Keryx Biopharmaceuticals Inc (KERX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Keryx Biopharmaceuticals Inc (Keryx) develops and commercializes new therapies for the treatment of renal disease. The company’s lead product Auryxia (ferric citrate) is an FDA approved oral, absorbable iron-based compound. It has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. Auryxia is used in the treatment of chronic kidney disease, renal diseases and iron deficiency anemia. This product is also marketed in Japan under the brand name Riona through its Japanese partner Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd, and in Europe as Fexeric. The company operates through its subsidiaries and also has its operational presence with its offices located in Israel, the US, and the UK. Keryx is headquartered in New York, the US.
Keryx Biopharmaceuticals Inc Key Recent Developments
Mar 01,2017: Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results
Nov 09,2016: Keryx Biopharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update
Aug 01,2016: Keryx Biopharmaceuticals Announces Second Quarter 2016 Financial Results
Jun 27,2016: Douglas Jermasek to Join Keryx Biopharmaceuticals as Vice President, Marketing and Strategy
Jun 21,2016: Keryx Biopharmaceuticals Appoints Two New Board Members
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Keryx Biopharmaceuticals Inc - Key Facts 5
Keryx Biopharmaceuticals Inc - Key Employees 6
Keryx Biopharmaceuticals Inc - Key Employee Biographies 7
Keryx Biopharmaceuticals Inc - Major Products and Services 8
Keryx Biopharmaceuticals Inc - History 9
Keryx Biopharmaceuticals Inc - Company Statement 11
Keryx Biopharmaceuticals Inc - Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Section 2 – Company Analysis 14
Keryx Biopharmaceuticals Inc - Business Description 14
Keryx Biopharmaceuticals Inc - Corporate Strategy 15
Keryx Biopharmaceuticals Inc - SWOT Analysis 16
SWOT Analysis - Overview 16
Keryx Biopharmaceuticals Inc - Strengths 16
Keryx Biopharmaceuticals Inc - Weaknesses 17
Keryx Biopharmaceuticals Inc - Opportunities 18
Keryx Biopharmaceuticals Inc - Threats 19
Keryx Biopharmaceuticals Inc - Key Competitors 20
Section 3 – Company Financial Ratios 21
Financial Ratios - Capital Market Ratios 21
Financial Ratios - Annual Ratios 22
Performance Chart 24
Financial Performance 24
Financial Ratios - Interim Ratios 25
Financial Ratios - Ratio Charts 26
Section 4 – Company’s Lifesciences Financial Deals and Alliances 27
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 28
Keryx Biopharmaceuticals Inc, Recent Deals Summary 29
Section 5 – Company’s Recent Developments 30
Mar 01, 2017: Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results 30
Nov 09, 2016: Keryx Biopharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update 32
Aug 01, 2016: Keryx Biopharmaceuticals Announces Second Quarter 2016 Financial Results 34
Jun 27, 2016: Douglas Jermasek to Join Keryx Biopharmaceuticals as Vice President, Marketing and Strategy 35
Jun 21, 2016: Keryx Biopharmaceuticals Appoints Two New Board Members 36
Apr 28, 2016: Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results 37
Apr 01, 2016: Keryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors 39
Feb 25, 2016: Keryx Biopharmaceuticals Announces Fourth Quarter and Year-End 2015 Financial Results 40
Section 6 – Appendix 42
Methodology 42
Ratio Definitions 42
About GlobalData 46
Contact Us 46
Disclaimer 46List of Tables
Keryx Biopharmaceuticals Inc, Key Facts 5
Keryx Biopharmaceuticals Inc, Key Employees 6
Keryx Biopharmaceuticals Inc, Key Employee Biographies 7
Keryx Biopharmaceuticals Inc, Major Products and Services 8
Keryx Biopharmaceuticals Inc, History 9
Keryx Biopharmaceuticals Inc, Subsidiaries 13
Keryx Biopharmaceuticals Inc, Key Competitors 20
Keryx Biopharmaceuticals Inc, Ratios based on current share price 21
Keryx Biopharmaceuticals Inc, Annual Ratios 22
Keryx Biopharmaceuticals Inc, Annual Ratios (Cont...1) 23
Keryx Biopharmaceuticals Inc, Interim Ratios 25
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 28
Keryx Biopharmaceuticals Inc, Recent Deals Summary 29
Currency Codes 42
Capital Market Ratios 42
Equity Ratios 43
Profitability Ratios 43
Cost Ratios 44
Liquidity Ratios 44
Leverage Ratios 45
Efficiency Ratios 45List of Figures
Keryx Biopharmaceuticals Inc, Performance Chart (2012 - 2016) 24
Keryx Biopharmaceuticals Inc, Ratio Charts 26
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 28
Onyx Pharmaceuticals Inc
Millennium Pharmaceuticals Inc
Genzyme Corp
Fresenius Medical Care AG & Co KGaA
Astex Pharmaceuticals Inc
Akebia Therapeutics Inc
